Oral antibodies to human papillomavirus type 16 in women with cervical neoplasia

• Published in: Journal of medical virology 2001-09, Vol.65 (1), p.149-154
• Main Authors: Marais, Dianne J., Best, Jennifer M., Rose, Robert C., Keating, Patrick, Soeters, Robbert, Denny, Lynnette, Dehaeck, Catherine M.C., Nevin, James, Kay, Patti, Passmore, Jo-Ann, Williamson, Anna-Lise
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; antibodies; Antibodies, Viral - analysis; Antibodies, Viral - blood; Biological and medical sciences; Carcinoma, Squamous Cell - virology; cervical cancer; Cervical Intraepithelial Neoplasia - virology; cervical neoplasia; Child; Child, Preschool; DNA, Viral - analysis; Female; Fundamental and applied biological sciences. Psychology; HPV-16; Human papillomavirus 16; Humans; Male; Microbiology; Middle Aged; Mouth Mucosa - immunology; oral; Papillomaviridae - genetics; Papillomaviridae - immunology; Papillomaviridae - isolation & purification; Papillomavirus Infections - virology; Tumor Virus Infections - virology; Uterine Cervical Neoplasms - virology
• ISSN: 0146-6615; 1096-9071
• DOI: 10.1002/jmv.2014

This study investigated the relationship between human papillomavirus type 16 (HPV‐16) antibodies detected in oral fluid from women with cervical neoplasia, their HPV‐16 antibody seroprevalence, and their cervical HPV‐16 DNA presence. Cervical HPV‐16 DNA was detected by polymerase chain reaction in 43.2% (35/81) of these women. The prevalence of IgG and IgA antibodies to HPV‐16 virus‐like particles (VLP‐16) in oral fluid and was investigated by enzyme‐linked immunosorbent assay. Anti‐VLP‐16 IgA antibodies were detected in oral fluid from 54.3% (44/81) of women with cervical neoplasia, compared with 8% (3/36) in controls (P = 0.000002). Anti‐VLP‐16 IgG was detected in oral fluid from 43.2.9% (25/72) and 13.3% (4/30; P = 0.029), respectively. Women who were HPV‐16 DNA positive at their cervical lesion, displayed an oral fluid anti‐VLP‐16 IgA prevalence of 60.7% (17/28) and HPV‐16 DNA negative women an oral fluid anti‐VLP‐16 IgA prevalence of 50% (20/40; P = 0.38). Oral fluid anti‐VLP‐16 IgG prevalence in HPV‐16 DNA positive women was 28.6% (8/28) compared with 40% (16/40) in oral fluid from HPV‐16 DNA negative women (P = 0.3). Amongst HPV‐16 DNA positive women, the anti‐VLP‐16 IgG seroprevalence was 75% (21/28) and IgA seroprevalence 35.7% (10/28) and for the HPV‐16 DNA negative women these values were 60% (24/40) and 32.5% (13/40), respectively. Oral IgA antibody testing proved no more sensitive than serum antibody detection for the determination of HPV infection but could be useful as a non‐invasive screening method for women with cervical neoplasia and for estimating the mucosal antibody response to HPV vaccines. J. Med. Virol. 65:149–154, 2001. © 2001 Wiley‐Liss, Inc.